MeiraGTx Holdings plc (MGTX) stock
Close on Nov 11, 2026Market cap $929.70MP/E 12.1Yield –
MeiraGTx Holdings plc grew revenue 1365.9% to $401.91M over the twelve months to Sep 30, 2026. Free cash flow was -$2.99M. At the latest close the market valued the company at $929.70M, 12.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $929.70M
- P/E ratio
- 12.1
- Price to sales
- 2.31
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.32%
Fundamentals
- Revenue
- $401.91M
- Net income
- $78.28M
- EPS, diluted
- $0.80
- Free cash flow
- -$2.99M
- Diluted shares
- 97M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $9.62
- Open
- $9.70
- Day's range
- $9.53 – $9.76
- Volume
- 455,941
- Average volume (20 days)
- 620,787
- Beta (5 years)
- 1.59
- 52-week range
- $6.62 – $15.35
- RSI (14 days)
- 47.4
- Volatility (1 year)
- 58.7%
- Relative volume
- 0.59×
- WACC
- 12.0%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MGTX | S&P 500 | Difference | MGTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.4% | -2.4% | −7.0 pts | ||
| 3 months | -25.8% | -1.2% | −24.7 pts | ||
| Year to date | +21.8% | +12.3% | +9.5 pts | ||
| 1 year | +8.8% | +12.4% | −3.7 pts | ||
| 3 years | +101.2% | +78.8% | +22.4 pts | +26.3% | +21.4% |
| 5 years | -51.1% | +75.2% | −126.3 pts | -13.3% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MeiraGTx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Update
About MeiraGTx
Biological Products, (No Diagnostic Substances)
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company focused on developing locally delivered genetic therapies for serious inherited and common disorders. Its clinical pipeline targets conditions including radiation-induced xerostomia, Parkinson’s disease, and inherited retinal dystrophies. The company designs and produces gene therapy candidates using internal end-to-end good manufacturing practices capabilities, encompassing viral vector production, plasmid DNA manufacturing, and quality control. In addition to therapeutic candidates, the enterprise develops proprietary technologies such as an oral small molecule-controlled synthetic riboswitch gene regulation platform, specialized delivery devices for central nervous system administration, and a T-cell progenitor cell therapy platform. Its pipeline activities serve patients through clinical research and strategic development collaborations with global pharmaceutical partners.
Company profile, executives and historyMeiraGTx stock: common questions
What is MeiraGTx's stock price?
MGTX closed at $9.68 on Nov 11, 2026, up 0.62% on the day. Over the past 52 weeks it traded between $6.62 and $15.35.
What is MeiraGTx's market cap?
MeiraGTx was worth $929.70M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MGTX's P/E ratio?
MGTX trades at 12.1 times earnings, based on diluted earnings per share of $0.80 over the twelve months to Sep 30, 2026.
How much revenue does MeiraGTx make?
MeiraGTx reported revenue of $401.91M for the twelve months to Sep 30, 2026, up 1365.9% from a year earlier.
Does MeiraGTx pay a dividend?
No. MeiraGTx has not paid a cash dividend over the last twelve months.
When does MeiraGTx report earnings next?
MeiraGTx is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MGTX stock performed over the past year?
Including dividends, MGTX returned +8.8% over the past year, against +12.4% for the S&P 500.
How many MGTX shares are sold short?
7M shares were sold short at the latest FINRA report, 10.67% of the float, or 10.8 days of average trading volume.
Who are MeiraGTx's competitors?
Companies most similar to MeiraGTx by business, industry and size include KRYS, MAZE, RGNX, VIR, ALVO.
See a number that looks wrong?